Eli Lilly and Company (NYSE:LLY) Price Target Raised to $1,500.00

Key Points

• JPMorgan raised Eli Lilly’s price target to $1,500 from $1,400 and maintained an “overweight” rating, implying 26.65% potential upside from the prior close.
• Analyst sentiment remains favorable, with 26 of 30 analysts assigning Buy or Strong Buy ratings; MarketBeat reports a “Moderate Buy” consensus and an average target price of $1,311.96.
• Lilly reported strong quarterly results, posting $8.38 in EPS versus the $6.40 consensus estimate and $22.97 billion in revenue, up 47.7% year over year. Growth is being driven largely by its diabetes and obesity medicines, though pricing pressure and slower oral GLP-1 rollout remain risks.

Eli Lilly and Company (NYSE:LLY - Get Free Report) had its price objective increased by research analysts at JPMorgan Chase & Co. from $1,400.00 to $1,500.00 in a research note issued on Monday. The firm presently has an "overweight" rating on the stock. JPMorgan Chase & Co.'s target price points to a potential upside of 26.65% from the company's previous close.

LLY has been the subject of a number of other research reports. Weiss Ratings upgraded Eli Lilly and Company from a "buy (b-)" rating to a "buy (b)" rating in a research report on Wednesday, August 26th. Sanford C. Bernstein boosted their target price on Eli Lilly and Company from $1,300.00 to $1,385.00 and gave the stock an "outperform" rating in a research report on Tuesday, July 14th. Wells Fargo & Company upped their target price on Eli Lilly and Company from $1,280.00 to $1,330.00 and gave the company an "overweight" rating in a report on Thursday, August 6th. Wall Street Zen lowered Eli Lilly and Company from a "strong-buy" rating to a "buy" rating in a research report on Sunday, August 23rd. Finally, Royal Bank Of Canada lifted their price target on Eli Lilly and Company from $1,250.00 to $1,500.00 and gave the stock an "outperform" rating in a research note on Wednesday, July 8th. One analyst has rated the stock with a Strong Buy rating, twenty-five have issued a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $1,311.96.

Eli Lilly and Company Stock Performance

NYSE:LLY opened at $1,184.38 on Monday. The company has a 50-day moving average of $1,177.12 and a 200-day moving average of $1,083.30. The firm has a market cap of $1.11 trillion, a price-to-earnings ratio of 39.74, a price-to-earnings-growth ratio of 1.46 and a beta of 0.50. The company has a current ratio of 1.35, a quick ratio of 1.00 and a debt-to-equity ratio of 1.41. Eli Lilly and Company has a twelve month low of $716.08 and a twelve month high of $1,292.65.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last released its earnings results on Wednesday, August 5th. The company reported $8.38 EPS for the quarter, topping analysts' consensus estimates of $6.40 by $1.98. Eli Lilly and Company had a net margin of 33.53% and a return on equity of 97.83%. The business had revenue of $22.97 billion for the quarter, compared to the consensus estimate of $20.82 billion. During the same period in the previous year, the firm earned $6.31 EPS. The business's revenue for the quarter was up 47.7% on a year-over-year basis. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. Analysts forecast that Eli Lilly and Company will post 36.62 earnings per share for the current fiscal year.

Insider Activity at Eli Lilly and Company

In related news, EVP Patrik Jonsson sold 6,500 shares of the stock in a transaction dated Monday, August 17th. The stock was sold at an average price of $1,175.10, for a total value of $7,638,150.00. Following the completion of the sale, the executive vice president directly owned 54,147 shares of the company's stock, valued at approximately $63,628,139.70. This represents a 10.72% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Anat Hakim sold 5,000 shares of the firm's stock in a transaction dated Friday, August 7th. The stock was sold at an average price of $1,190.00, for a total value of $5,950,000.00. Following the sale, the executive vice president owned 11,875 shares of the company's stock, valued at $14,131,250. The trade was a 29.63% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 13,500 shares of company stock valued at $15,958,170. Company insiders own 0.14% of the company's stock.

Institutional Investors Weigh In On Eli Lilly and Company

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in LLY. Bank of America Corp DE acquired a new stake in Eli Lilly and Company during the second quarter valued at $13,522,666,000. Jupiter Topco LLC purchased a new position in Eli Lilly and Company in the second quarter valued at about $4,667,180,000. Fifth Third Bancorp increased its position in Eli Lilly and Company by 321.3% in the 1st quarter. Fifth Third Bancorp now owns 1,963,490 shares of the company's stock worth $1,805,959,000 after purchasing an additional 1,497,423 shares during the last quarter. Assenagon Asset Management S.A. increased its position in Eli Lilly and Company by 353.7% in the 1st quarter. Assenagon Asset Management S.A. now owns 1,550,234 shares of the company's stock worth $1,425,859,000 after purchasing an additional 1,208,510 shares during the last quarter. Finally, Corient Private Wealth LP purchased a new stake in shares of Eli Lilly and Company during the 2nd quarter worth about $764,116,000. Hedge funds and other institutional investors own 82.53% of the company's stock.

Eli Lilly and Company News Roundup

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Citigroup sees substantial upside. Citigroup estimates a potential 35% gain for LLY, supported by the company’s leadership in GLP-1 medicines, expanding indications and long-term demand. The bank nevertheless highlighted pricing headwinds and a slower-than-expected oral GLP-1 rollout as risks. Citigroup outlook for Eli Lilly
• Positive Sentiment: Oral GLP-1 momentum is improving. CEO David Ricks said Foundayo represents about one-third of new patients starting an oral GLP-1, while Lilly’s share of the pill market is increasing weekly. The company is also building a $6.5 billion Houston manufacturing facility, potentially supporting future supply and revenue growth. Lilly oral GLP-1 expansion
• Positive Sentiment: Medicare coverage is broadening the customer base. Approximately 700,000 seniors reportedly began GLP-1 treatment after Medicare obesity-drug coverage started in July, with about 70% using Lilly medicines such as Zepbound and Foundayo. This could extend the company’s obesity-drug growth trajectory. Senior GLP-1 demand
• Positive Sentiment: Regulatory wins are expanding Lilly’s portfolio. The FDA approved a once-weekly insulin treatment and expanded Olumiant’s approval to patients aged 12 and older with severe alopecia areata, creating additional commercial opportunities beyond the company’s largest growth drivers. Lilly weekly insulin approval
• Neutral Sentiment: Global access initiative may strengthen Lilly’s reputation. Lilly launched the Change the Course Commitment to expand access to diabetes and obesity medicines in low- and middle-income countries, targeting treatment parity with high-income countries before 2040. The initiative could support long-term reach but may also increase access-related costs. Lilly Change the Course Commitment
• Negative Sentiment: Investors face pricing and execution concerns. Analysts warn that pricing pressure and a slower oral GLP-1 launch could limit near-term upside despite strong demand. A jury also awarded Nektar $90 million in litigation involving Lilly, although the stock’s limited reaction suggests investors view the financial impact as manageable. Nektar jury award involving Lilly

Eli Lilly and Company Company Profile

Eli Lilly and Company is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for a range of medical conditions. Its portfolio includes treatments for diabetes and obesity, oncology, immunology, neuroscience, cardiovascular disease and other areas of significant unmet medical need.

The company's products include Mounjaro and Trulicity for diabetes, Zepbound for chronic weight management, and insulin products such as Humalog. Lilly also markets Verzenio for certain breast cancers and Kisunla for the treatment of early symptomatic Alzheimer's disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.